Talquetamab (Talvey, Johnson & Johnson Innovative Medicine) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 antibody and have demonstrated disease progression on the last therapy'.
The dosage schedule is available in the summary of product characteristics for talquetamab.
The list price for talquetamab is £326.41 per 3‑mg vial and £4,352.00 per 40‑mg vial (excluding VAT, BNF online accessed October 2025).
The company has a commercial arrangement. This makes talquetamab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Johnson & Johnson Innovative Medicine's webpage on their responsibility to the planet.